Saturday 17 October 2026
Export PLUR’s income statement to Excel — free account
Pluri Inc.
PLUR Healthcare Biotechnology
Pluri Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.0 million, down 24.0% from fiscal 2025. In the quarter to June 2026, revenue fell 15.8%, EPS grew 48.0%, free cash flow grew 25.0% and total debt rose 3.43%, each against the same quarter a year earlier.
0.93
0.01
−1.06%
Follow PLUR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 3 | 1 |
| 789.88% | 430.96% | 408.10% | 260.35% | ||
| (65.26%) | (85.06%) | (80.48%) | (74.95%) | ||
ROIC |
(227.46%) | (252.28%) | (306.99%) | (526.92%) | |
Return on Tangible Assets |
167.35% | 155.40% | 128.53% | 106.23% | |
Average Days of Receivables |
80.93 | 46.07 | 33.49 | 31.25 | |
Free Cash Flow per Share |
(2.35) | (2.38) | (2.16) | (2.07) | |
Free Cash Flow |
(21.10) | (22.01) | (21.69) | (20.20) | |
Capital Expenditures |
(1.53) | (1.86) | (1.33) | (0.61) | |
| Other line items | |||||
Cash ROIC |
(56.45%) | (69.72%) | (88.92%) | (108.48%) | |
Accounts Receivable Turnover |
8.09 | 8.67 | 7.79 | 6.29 | |
Accounts Payable Turnover |
0.34 | 0.34 | 0.29 | 0.25 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
1,057.39 | 1,122.55 | 1,261.18 | 1,546.23 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,047.74% | 1,104.85% | 1,456.26% | 1,485.43% | |
Selling, General and Administrative Expense of Revenue |
754.45% | 793.65% | 997.59% | 1,013.68% | |
Share Based Compensation of Revenue |
221.34% | 257.06% | 378.87% | 366.73% | |
Interest Coverage |
(26.36) | (27.49) | (27.97) | (26.76) | |
Operating CF/Net income |
0.87 | 0.77 | 0.80 | 0.82 | |
Depreciation/Fixed assets |
0.22 | 0.26 | 0.30 | 0.33 | |
Capex/Depreciation |
(4.01) | (4.21) | (2.67) | (1.20) | |
Revenue per Share |
0.15 | 0.14 | 0.11 | 0.10 | |
Operating CF per Share |
(2.18) | (2.18) | (2.02) | (2.01) | |
Capex per Share |
(0.17) | (0.20) | (0.13) | (0.06) | |
Capex to Sales |
1.15 | 1.39 | 1.23 | 0.61 |
Columns are period end dates